Neurology
Wrap-Up: Vyvgart Targets Four Populations at AAN 2026
A Summary of the 2026 AAN Annual Meeting for Rare Diseases from a Managed Care Perspective – Myasthenia
Rayan Salih · April 30, 2026 · 9 min
Living with Myasthenia Gravis
Stories from people navigating Myasthenia Gravis — diagnosis, treatment, caregiving, and the ordinary days in between.
6 stories
Neurology
Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
ADAPT Jr data show 80% of adolescent gMG patients achieved minimal symptom expression by cycle two with efgartigimod at AAN 2026.
Rayan Salih · 7 min read
Neurology
Ocular Myasthenia Gravis Gets Its First Targeted Biologic Candidate
Phase 3 ADAPT OCULUS data at AAN 2026 show efgartigimod significantly improves ocular MG symptoms, supporting a planned FDA sBLA submission for the oMG indication.
Rayan Salih · 2 min read
Neurology
Vyvgart Crosses the Antibody Line in Seronegative Myasthenia Gravis
Phase 3 ADAPT SERON data at AAN 2026 show efgartigimod significantly improves MG-ADL scores in seronegative gMG patients, with FDA priority review targeting May 10, 2026.
Rayan Salih · 8 min read
Neurology
Phase 2b Biomarker Analysis: BCMA CAR-T in Myasthenia Gravis
CAR-T cells that have been redirected to B cell maturation antigen (BCMA) may also be useful for treating
Rayan Salih · 3 min read
Neurology
Acetylcholine Receptor-Positive Myasthenia Gravis in Older Patients
Acetylcholine receptor-positive myasthenia gravis (AChR-positive MG) is an autoimmune disease that leads to Fatigable weakness, often fluctuating in
Dr. Abu Bakar · 13 min read
Questions clinicians ask
- How does acetylcholine receptor-positive myasthenia gravis present in older patients?
- The brief characterizes acetylcholine receptor-positive myasthenia gravis in older patients as an autoimmune disease causing fatigable, often fluctuating weakness. Its scope is limited to older adults with detectable acetylcholine receptor antibodies and does not establish a specific treatment strategy.
- What does the phase 2b biomarker evidence suggest about BCMA-directed CAR-T therapy for myasthenia gravis?
- The biomarker analysis suggests that CAR-T cells redirected against B cell maturation antigen may have therapeutic potential in myasthenia gravis. This remains investigational evidence, and the brief does not provide enough information to define comparative efficacy, safety, or routine clinical use.
- What does the evidence show for efgartigimod in seronegative generalized myasthenia gravis?
- Phase 3 evidence indicates that efgartigimod improves MG-ADL scores in patients with seronegative generalized myasthenia gravis. The findings extend the potential applicability of FcRn-directed therapy beyond antibody-positive disease, although regulatory review is still pending for this population.
- What evidence supports efgartigimod in ocular and adolescent myasthenia gravis?
- Phase 3 data in ocular myasthenia gravis show improvement in ocular symptoms and support pursuit of a targeted indication. Separate pediatric data show that many adolescents with generalized myasthenia gravis achieved minimal symptom expression by the second treatment cycle, providing early support for use in younger patients.
Other conditions
One story a day
The story of the day, in your inbox
One health journey each morning — no advice, no alarm, just company for the road.